

	Satya-Murti	Atkinson	Cox	Eng	Fischer	Hayes	Janjan	Kaul	Matuszewski	Scheuner	Teutsch	Juhn	Jeter	Mansfield	Pao	Voting Member Average	Overall Average
1	How confident are you that there is sufficient evidence to determine whether pharmacogenomic testing affects health outcomes (including benefits and harms) for patients with cancer whose anticancer treatment strategy is guided by the results of testing as described below? (Please consider this question separately for each test in the following clinical situations.)																
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence																
a) CYP2D6 for breast cancer patients who are candidates for tamoxifen	2	2	2	1	2	1	2	3	3	2	2	3	2	2	2	2.00	2.07
b) UGT1A1 for colon cancer patients who are candidates for irinotecan	2	2	1	2	2	2	2	2	3	2	2	2	2	1	2	2.00	1.93
c) HER2/neu for breast cancer patients who are candidates for trastuzumab	4	5	5	4	4	4	4	4	4	5	4	4	4	5	5	4.27	4.33
d) BCR-ABL for chronic myelogenous leukemia patients who are candidates for imatinib																	
1) Diagnosis and Monitoring	4	5	5	3	5	4	5	5	3	5	4	4	5	5	5	4.96	4.47
2) Point to detect treatment failure	1	3	2	1	2	3	2	2	2	3	3	4	2	3	4	2.18	2.47
e) K-ras for metastatic colorectal cancer patients who are candidates for cetuximab and/or panitumumab	4	4	5	4	5	4	4	4	4	5	4	5	5	4	5	4.27	4.40

2	Satya-Murti	Atkinson	Cox	Eng	Fischer	Hayes	Janjan	Kaul	Matuszewski	Scheuner	Teutsch	Juhn	Jeter	Mansfield	Pao	Voting Member Average	Overall Average
For those items where the answer to Question 1 is at least in the Intermediate range (mean score >2.5), how confident are you that pharmacogenomic testing improves health outcomes for patients with cancer whose anticancer treatment strategy is guided by the results of testing as described below? (Please consider this question separately for each test in the following clinical situations.)																	
1 <i>Low Confidence</i> -2- 3 <i>Intermediate Confidence</i> -4- 5 <i>High Confidence</i>																	
a) CYP2D6 for breast cancer patients who are candidates for tamoxifen																	
b) UGT1A1 for colon cancer patients who are candidates for irinotecan																	
c) HER2/neu for breast cancer patients who are candidates for	3	5	5	4	5	5	4	5	5	5	4	5	5	5	5	4.55	4.67

trastuzumab																	
d) BCR-ABL for chronic myelogenous leukemia patients who are candidates for imatinib																	
1) Diagnosis and Monitoring	4	4	5	4	4	4	5	5	3	5	4	4	5	4	5	4.27	4.33
2) Point to detect treatment failure																	
e) K-ras for metastatic colorectal cancer patients who are candidates for cetuximab and/or panitumumab	4	4	5	4	5	5	4	4	4	5	4	5	4	3	5	4.36	4.33

3	Satya-Murti	Atkinson	Cox	Eng	Fischer	Hayes	Janjan	Kaul	Matuszewski	Scheuner	Teutsch	Juhn	Jeter	Mansfield	Pao	Voting Member Average	Overall Average
How confident are you that these conclusions are generalizable to:																	
<i>1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence</i>																	
a) community based setting	3	4	5	3	5	5	5	5	4	4	3	3	5	4	5	4.18	4.20
b) the Medicare beneficiary population	2	3	5	4	5	5	5	5	5	4	3	3	5	5	5	4.18	4.27